Using computational approaches and targeted experimentation our researchers are seeking potential therapeutic targets for CVDs. The rationale is to reduce the unsustainably high rate of failures of compounds (eg, darapladib) before initiation of costly clinical trials by using approaches that can help: (i) identify novel causal pathways that underpin discovery of new drug targets, (ii) infer the causal relevance to CVD of suspected targets, and (iii) anticipate potential safety concerns.